Critical factors determining the potency of topical corticosteroids

Journal of Dermatological Treatment

Volumn 17, Issue 3, 2006, Pages 133-135

  Kirkland, Ryan ^a   Pearce, Daniel ^a   Balkrishnan, Rajesh ^b   Feldman, Steven ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Adherence; Psoriasis; Treatment

Indexed keywords

CORTICOSTEROID; CORTICOSTEROID RECEPTOR; DRUG VEHICLE; EMULSIFYING AGENT; FATTY ACID; FLUOCINOLONE ACETONIDE; PROPYLENE GLYCOL; SURFACTANT;

ASSAY; BIOEQUIVALENCE; CLINICAL PRACTICE; CREAM; DOCTOR PATIENT RELATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FOAM; GEL; HUMAN; OINTMENT; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PSORIASIS; RELIABILITY; REVIEW; TOPICAL TREATMENT; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VASOCONSTRICTOR ASSAY;

ADMINISTRATION, CUTANEOUS; GLUCOCORTICOIDS; HUMANS; PSORIASIS; SKIN; VASOCONSTRICTION;

EID: 33746626898     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600845370     Document Type: Review

References (13)

1. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. Drugs. 1988;36(suppl 5):51-61.
2. Stoughton RB. The vasoconstrictor assay in bioequivalence testing: Practical concerns and recent developments. Int J Dermatol. 1992;Suppl 1:26-8.
3. Cornell RC. Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay. Int J Dermatol. 1992;31(suppl 1):38-40.
4. Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroid potency. Pediatr Dermatol. 1996;13:239-45.
5. Van de Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol. 2003;16:69-83.
6. Gao HY, Li Wan Po A. Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity? Eur J Clin Pharmacol. 1994;46:71-5.
7. Fritz KA, Weston WL. Topical glucocorticosteroids. Ann Allergy. 1983;50:68-76.
8. Barry BW. Bioavailability of topical steroids. Dermatologica. 1976;152(suppl 1):47-65.
9. Hodari KT, Nanton JR, Carroll CL, Feldman SR, Balkrishnan R. Adherence in dermatology: A review of the last 20 years. J Dermatol Treatment. (in press).
10. Feldman SR, Housman TS. Patient's vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4:221-4.
11. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-6.
12. Van de Kerkhof PC, Steegers-Theunissen RP, Kuipers M. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197:31-6.
13. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212-16.